Paola Marcovecchio
Senior Principal Scientist Pfizer
Seminars
Thursday 17th September 2026
Beyond Bispecifics: Novel Modalities Increase the Therapeutic Window & Durability Of Next-Generation TCEs
9:00 am
- New TCE designs are necessary to crack the code of solid-tumor TCEs and address relapsed/refractory heme malignancies
- Better biological data packages are necessary to design avidity-driven modalities
- CD3 affinity needs to be developed in the context of the modality with more thoughtful clinical dosing regimens
